AAV vectors encoding NF1 and uses thereof

NZ837342APending Publication Date: 2026-09-25UNIV OF MASSACHUSETTS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ837342
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-09-24
Filing Date
2021-09-23
Publication Date
2026-09-25

Smart Images

  • Figure 1_ABST
    Figure 1_ABST
Patent Text Reader

Abstract

Aspects of the disclosure relate to compositions and methods of treating certain genetic disease (e.g., Neurofibromatosis type I) by delivering functional neurofibromin 1(NF1) protein (e.g., mini-NF1 protein and / or full-length NF1 protein) to target cell (e.g., cells and / or tissue of a subject). The disclosure is based, in part, on isolated nucleic acids (e.g., rAAV vectors) and rAAVs engineered to express a functional NF1 protein (e.g., mini-NF1 protein and / or full-length NF1 protein) or variants thereof.
Need to check novelty before this filing date? Find Prior Art